Cellectar director granted 25,000 stock options

Cellectar Biosciences director Frederick W. Driscoll received a grant of stock options representing 25,000 shares of common stock.

Rhea-AI Filing Summary

Cellectar Biosciences director Frederick W. Driscoll received a grant of stock options representing 25,000 shares of common stock. The options have an exercise price of $2.70 per share and expire on July 7, 2036. They vest in full on July 7, 2027, subject to his continued service, and this grant brings his reported option holdings from this award to 25,000 derivative securities.

Insider Trade Summary

Grant/Award: 25,000 shares

Grant/Award 1 txn

Insider DRISCOLL FREDERICK W

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	25,000	$0.00	$0.00

Holdings After Transaction: Stock option (right to buy) — 25,000 contracts (Direct)

Footnotes (1)

1. F1. This option shall vest in full on July 7, 2027, subject to the reporting person's continued service through the applicable vesting date.

Key Figures

Options granted: 25,000 options Exercise price: $2.70 per share Expiration date: July 7, 2036 +2 more

5 metrics

Options granted 25,000 options Stock option award to director Frederick W. Driscoll

Exercise price $2.70 per share Strike price for the granted stock options

Expiration date July 7, 2036 Option term end date for the grant

Vesting date July 7, 2027 Options vest in full on this date, subject to service

Underlying shares 25,000 shares Common stock underlying the stock option award

Key Terms

Stock option (right to buy), exercise price, Common stock, vesting

4 terms

Stock option (right to buy) financial

"security_title: Stock option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 2.7000"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Common stock financial

"underlying_security_title: Common stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

vesting financial

"This option shall vest in full on July 7, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Cellectar Biosciences (CLRB) disclose for Frederick W. Driscoll?

Cellectar Biosciences reported that director Frederick W. Driscoll received a grant of stock options for 25,000 shares. These options are a compensation-related award, not an open-market share purchase or sale, and give him the right to buy common stock at a fixed price.

How many Cellectar (CLRB) stock options were granted to Frederick W. Driscoll?

Frederick W. Driscoll was granted stock options covering 25,000 shares of Cellectar common stock. The Form 4 identifies this as a derivative security award tied to the company’s common stock, increasing his option-based exposure by that amount through this grant.

What is the exercise price of Frederick W. Driscoll’s new Cellectar (CLRB) options?

The new stock options for Frederick W. Driscoll have an exercise price of $2.70 per share. This means he can choose to purchase Cellectar common stock at $2.70 per share once the options are vested and before they expire, subject to the award terms.

When do Frederick W. Driscoll’s Cellectar (CLRB) stock options vest and expire?

The granted stock options vest in full on July 7, 2027, provided Driscoll continues serving through that date. The options carry an expiration date of July 7, 2036, giving a long exercise window after vesting, according to the Form 4 disclosure and related footnote.

Is Frederick W. Driscoll’s Cellectar (CLRB) option grant an open-market buy or sell?

The filing describes this as a grant or award acquisition of stock options, not an open-market transaction. Driscoll did not buy or sell shares in the market; instead, he received 25,000 options as compensation with a defined exercise price and vesting schedule.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/08/2026 - 09:10 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DRISCOLL FREDERICK W

(Last) (First) (Middle)

C/O CELLECTAR BIOSCIENCES, INC.

100 CAMPUS DRIVE

(Street)

FLORHAM PARK NEW JERSEY 07932

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cellectar Biosciences, Inc. [ CLRB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$2.7	07/07/2026		A		25,000		(1)	07/07/2036	Common stock	25,000	$0	25,000	D

Explanation of Responses:

1. This option shall vest in full on July 7, 2027, subject to the reporting person's continued service through the applicable vesting date.

	/s/ Chad Kolean, attorney-in-fact for Frederick Driscoll	07/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)